No I didn’t sell and it’s not only a problem i
Post# of 148161
A month ago we were trading between $4 and $5, this information would have pushed the SP north of that. Now our baseline is $2 ish - let’s just see if this information pushes us well past $5.
The bigger issue is that if we see mismanagement with the CD12 trial design, management and data why would we expect any change with CD16, or CD 17, or cancer or NASH?